The opportunistic pathogen Mycobacterium abscessus (Mab) causes fatal lung infections
that bear similarities—and notable differences—with tuberculosis (TB) pulmonary disease …

Conspectus Rifamycin antibiotics include the WHO essential medicines rifampin, rifabutin,
and rifapentine. These are semisynthetic derivatives of the natural product rifamycins …

Mycobacterium abscessus (Mab), a nontuberculous mycobacterial (NTM) species, is an
emerging pathogen with high intrinsic drug resistance. Current standard-of-care therapy …

Rifamycin antibiotics are a valuable class of antimicrobials for treating infections by
mycobacteria and other persistent bacteria owing to their potent bactericidal activity against …

The clinical utility of rifamycins against non-tuberculous mycobacterial (NTM) disease is
limited by intrinsic drug resistance achieved by ADP-ribosyltransferase Arr. By blocking the …

Mycobacterium abscessus has been recognised as a dreadful respiratory pathogen among
the non-tuberculous mycobacteria (NTM) because of misdiagnosis, prolonged therapy with …

Rifampicin is an effective drug for treating tuberculosis (TB) but is not used to treat
Mycobacterium abscessus infections due to poor in vitro activity. While rifabutin, another …

Mycobacterium abscessus has emerged as a successful pathogen owing to its intrinsic drug
resistance. Macrolide and lincosamide antibiotics share overlapping binding sites within the …

Mycobacterium abscessus, a leading cause of severe lung infections in
immunocompromised individuals, poses significant challenges for current therapeutic …

Aims We aimed to investigate the molecular mechanisms underlying the survival of
Mycobacterium abscessus when faced with antibiotic combination therapy. By conducting …